MedPath

Renoprotective effects of HMG/CoA reductase inhibitor on patients with hyperlipidemia associated with renal insufficiency-Effect of atorvastatin by switching from other statins

Not Applicable
Conditions
Diabetes Mellitus
Registration Number
JPRN-UMIN000007703
Lead Sponsor
Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

The exclusion criteria were an age >70 years, current history of myocardial infarction and/or cerebral stroke, uncontrollable hypertension and hyperglycemia, renal failure, abnormal liver or muscle enzymes (ALT>100, ALT>100), patients who applied for other clinical trial within 3 months, expectant mother, lactating woman, patients who had taken ACE-I and/or ARB within 3 months, inappropriate patients judged by the physician in charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath